Sahar Barjesteh van Waalwijk van Doorn-Khosrovani: The idea that early use of parp inhibitors would be beneficial, while late use would be harmful, lacks plausibility and a reasonable explanation.
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani shared some interesting insight regarding PARP inhibitors in her LinkedIn post:
“The idea that early use of parp inhibitors would be beneficial, while late use (after multiple lines of therapy) would be harmful, lacks plausibility and a reasonable explanation. Timothée Olivier & Vinay Prasad propose that PARP inhibitors in ovarian cancer need re-evaluation in all settings. One ‘explanation worth considering is patients who receive PARP early derive some benefit simply because they are less likely to receive the same agent later upon relapse. Some of the survival benefit in upfront trials might simply reveal survival decrement if the drug is given later.'”
For details: Click here
Source: Sahar Barjesteh van Waalwijk van Doorn-Khosrovani / LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023